Nvidia shares pop as analysts dismiss AI bubble concerns
DUBLIN - Goldman Sachs & Co. LLC reported its trading activity in Avadel Pharmaceuticals PLC (NASDAQ:AVPL) shares, according to a regulatory filing submitted Tuesday.
The investment bank disclosed that as of November 3, 2025, it held long positions totaling 1,803,768 ordinary shares (1.85% of outstanding shares) and short positions of 739,860 shares (0.75%) in the pharmaceutical company.
The filing, made under Rule 38.5(b) of the Irish Takeover Panel Act, detailed specific transactions executed on November 3, including multiple purchases at prices ranging from $18.92 to $18.94 per share and numerous sales at prices between $18.74 and $18.76.
Goldman Sachs also reported several securities borrowing transactions, including new borrowings of 206,500 shares and full returns of 47,360 shares.
The disclosure indicated that Goldman Sachs is acting as an advisor to Avadel Pharmaceuticals, suggesting the company may be involved in potential takeover activity. The filing was made in compliance with Irish regulations requiring disclosure of dealings by connected exempt principal traders.
Avadel Pharmaceuticals is an Ireland-based biopharmaceutical company that develops medications using its proprietary drug delivery technologies.
The information was disclosed in a regulatory press release filed with the London Stock Exchange's news service.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.